DuckWiseDuckWise Get the app

Archive › BIIB

BIIB trade ideas: every closed DuckWise idea on Biogen Inc.

DuckWise has published 1 idea on Biogen Inc. (BIIB, Stock) that has closed between November 2020 and January 2021. Each is listed below with the levels published before the position was taken and its result at close — 1 in profit, 0 at a loss.

1closed idea
1 / 0in profit / at a loss
+27.12%average result
81 daystypical holding period
OpenedClosedSideEntryStopProjectionCloseResultDays
Nov 9, 2020Jan 29, 2021Long228—295289.84+27.12%81

Prices in US dollars. Prices are as traded on the day. Result is the price change from the published entry to the published close plus dividends received while the idea was held (paid, for shorts), before fees, taxes and slippage. How results are counted.

BIIB questions and answers

Has DuckWise published trade ideas on BIIB?

Yes. DuckWise has published 1 idea on Biogen Inc. (BIIB) that closed between November 2020 and January 2021: 1 closed in profit and 0 at a loss. The average result was +27.12% from the published entry to the published close, dividends included.

What was the latest closed DuckWise idea on BIIB?

A long idea opened on November 9, 2020 with an entry of $228.00 and a price projection of $295.00. It closed on January 29, 2021 at $289.84, a result of +27.12% after 81 days.

How long did DuckWise hold its BIIB ideas?

The typical BIIB idea was held about 81 days from entry to close. DuckWise ideas are swing and position trades, not day trades.

Is there an open DuckWise idea on BIIB right now?

Not at the moment. When DuckWise publishes a new idea on BIIB, app subscribers get a push notification; it appears on this page once it closes.

Is this page a stock forecast for BIIB or a recommendation to buy it?

No. This page records closed ideas only. Each price projection was a published level for a model idea, not a forecast of where BIIB will trade. The research is general and impersonal, not a recommendation to buy or sell BIIB or any other security.

More trade ideas on the record

Every ticker in the archive · Track record by year

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. Does not pay dividends.

These are closed ideas, published for the record. They are general and impersonal research, not a recommendation to buy or sell BIIB or any other security.